Nektar Therapeutics

04/28/2026 | Press release | Distributed by Public on 04/28/2026 16:01

Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets

SAN FRANCISCO, April 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 7, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. The web broadcast of the conference call will be available for replay through June 7, 2026.

To access the conference call, please pre-register at Nektar Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call.

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422.

Nektar is headquartered in San Francisco, California. For further information, visit https://www.nektar.com and follow us on LinkedIn.

For Investors:

Vivian [email protected]

Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
[email protected]

For Media:

Susan Roberts
LifeSci Communications
202-779-0929
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-first-quarter-on-thursday-may-7-2026-after-close-of-us-based-financial-markets-302756324.html

SOURCE Nektar Therapeutics

Nektar Therapeutics published this content on April 28, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 28, 2026 at 22:01 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]